If you have a roadmap, why not use it? On Maxiom Group’s blog today, Taylor Burtis asks why more pharma companies aren’t using the Target Product Profile to guide their drug development efforts from the earliest stage. Click here for more. As she points, out, FDA has published a clear guidance document on how to do this. She also mentions a manufacturer who shaved six months and $350,000 off the development timeframe and cost by using the TPP for an NME application for an orphan drug.

Related posts:

1. Making Multi-Product Facilities Safe: Why Risk-MaPP Matters

   ISPE’s Risk-MaPP guide aims to bring standards within multi-use facilities in line with the risk- and science-based principles outlined in...

2. Pharmaceutical Quality and Lessons from Toyota: Thomas Friedli on Creating a Continuous Improvement Culture in Pharma

   "You can only achieve long-term savings if you have stable running equipment that enables stable and robust processes. This is...

3. “Product Assurance Technology”: A Pig of a Different Color?

   Are different interpretations of PAT merely means of applying lipstick to the same pig? Maybe we'd be better off by...

4. Book Excerpt: Building in Quality and Flexibility From Day One

   In this excerpt from "Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized...

5. Byrn: QbD Can Double the Number of Clinical Trials

   "Feasibility batches" are key to reducing the time to IND and solving the Critical Path problem. ...